Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
FY2026 revenue $19.46bn (+4.9%); operating margin 11.6%; net income $1.15bn.
Continuing operations; net income from continuing operations $1.42bn (+29%).
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Feb 2026: BD completed the spin-off of its Biosciences & Diagnostic Solutions business and its combination with Waters Corporation, so BD diagnostics products now sit with Waters; buyers should check which entity supplies them.
Data breaches, cyber incidents, regulator action and assurance status.
Dec 2024: CISA published an advisory on default credentials (CVE-2024-10476, CVSS 8.0) in several BD microbiology and lab systems including BACTEC, MAX and Phoenix M50; BD said it was deploying fixes through field service and no exploitation was reported. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Oct 2026: The FDA highlighted BD's updated recall of certain Alaris pump infusion sets that perform worse than previously disclosed at low rates, risking under- or over-infusion; BD reported no serious injuries or deaths as of Aug 2026.
Contract delivery, go-lives, terminations and disputes.
Jun 2025: BD announced a UK partnership with Better Meds on medication management. No contract terminations or disputes involving BD found in HSH's search of the last 24 months.